Skip to main content

Advertisement

SpringerLink
Log in

A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome

  • Letter to the Editors
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

A Letter to the Editors to this article was published on 19 May 2016

The Original Article was published on 01 April 2015

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Martin-Liberal J, Furness AJ, Joshi K, Peggs KS, Quezada SA, Larkin J (2015) Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report. Cancer Immunol Immunother 64(6):765–767. doi:10.1007/s00262-015-1689-1

    Article  PubMed  Google Scholar 

  2. Mekinist (trametinib) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation (2015)  

  3. Tafinlar (dabrafenib) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation (2015)

  4. Pembrolizumab (keytruda) [package insert]. Whitehouse Station, NJ: Merk & Co., Inc. (2015)

  5. Keytruda (pembrolizumab) [package insert]. Merck & Co., Inc., Whitehouse Station, NJ (2014)

Download references

Author information

Authors and Affiliations

  1. University of Rochester Medical Center, 601 Elmwood Avenue, Box 617, Rochester, NY, 14642, USA

    Elizabeth Hansen, Deepak Sahasrabudhe & Lynn Sievert

Authors
  1. Elizabeth Hansen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Deepak Sahasrabudhe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lynn Sievert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elizabeth Hansen.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hansen, E., Sahasrabudhe, D. & Sievert, L. A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome. Cancer Immunol Immunother 65, 765–767 (2016). https://doi.org/10.1007/s00262-016-1835-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-016-1835-4

Keywords

Search

Navigation